ViroPharma Continues Development Of Subcutaneous Cinryze Despite Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma announced Aug. 1 that it is halting a Phase IIb study of a subcutaneous formulation of Cinryze with Halozyme’s recombinant human hyaluronidase (rHuPH20) due to safety concerns. Meanwhile, it reported 22% sales growth year-over-year for its hereditary angioedema drug in the U.S.
You may also be interested in...
ViroPharma Talks Cinryze Sales, EU Launches
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.